The αvβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2694-2704

  Ten Hagen, Timo L M ^a   Seynhaeve, Ann L B ^a   De Wiel Ambagtsheer, Gisela Aan ^a   De Bruijn, Ernst A ^b   Van Tiel, Sandra T ^a   Ruegg, Curzio ^c,d   Meyring, Michael ^e   Grell, Matthias ^e   Goodman, Simon L ^e   Eggermont, Alexander M M ^a,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF FRIBOURG   (Switzerland)

^e MERCK KGAA   (Germany)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

alphaVbeta3; cilengitide; EMD 121974; isolated limb perfusion; melphalan; sarcoma

Indexed keywords

CILENGITIDE; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOLATED LIMB PERFUSION; ISOLATION PERFUSION; LIMB PERFUSION; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; LIMB SALVAGE; MALE; MELPHALAN; RATS; RATS, INBRED BN; RECEPTORS, VITRONECTIN; SARCOMA, EXPERIMENTAL; SNAKE VENOMS;

EID: 84875603514     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27940     Document Type: Article

References (50)

1. Carmeliet P,. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
2. Alghisi GC, Rüegg C,. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006; 13: 113-35.
3. Varner JA, Brooks PC, Cheresh DA,. Review: the integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun 1995; 3: 367-74.
4. Cheresh DA,. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 6471-5.
5. Malik RK,. Regulation of apoptosis by integrin receptors. J Pediatr Hematol Oncol 1997; 19: 541-5.
6. Scatena M, Almeida M, Chaisson ML, et al. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-93.
7. Brooks PC, Strömblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
8. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
9. Brooks PC, Clark RA, Cheresh DA,. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
10. Mitjans F, Sander D, Adán J, et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108: 2825-38.
11. Smith JW, Vestal DJ, Irwin SV, et al. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J Biol Chem 1990; 265: 11008-13.
12. Charo IF, Nannizzi L, Smith JW, et al. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol 1990; 111: 2795-800.
13. Smith JW, Cheresh DA,. Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem 1990; 265: 2168-72.
14. Cheng YF, Clyman RI, Enenstein J, et al. The integrin complex alpha v beta 3 participates in the adhesion of microvascular endothelial cells to fibronectin. Exp Cell Res 1991; 194: 69-77.
15. Denhardt DT, Guo X,. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-82.
16. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151-5.
17. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003: 39: 917-26.
18. Dechantsreiter MA, Planker E, Mathä B, et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999: 42: 3033-40.
19. Mas-Moruno C, Rechenmacher F, Kessler H,. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010; 10: 753-68.
20. Alghisi GC, Ponsonnet L, Rüegg C,. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009; 4: e4449.
21. Nisato RE, Tille JC, Jonczyk A, et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6: 105-19.
22. Buerkle MA, Pahernik SA, Sutter A, et al. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86: 788-95.
23. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 151-7.
24. Burke PA, DeNardo SJ, Miers LA, et al. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002; 94: 1320-31.
25. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124: 2719-27.
26. Burke PA, DeNardo SJ, Miers LA, et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62: 4263-72.
27. Bretschi M, Merz M, Komljenovic D, et al. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 2011; 26: 843-51.
28. Bäuerle T, Komljenovic D, Merz M, et al. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011; 128: 2453-62.
29. Eggermont AM, de Wilt JH, ten Hagen TL,. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 429-37.
30. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-3.
31. Seynhaeve AL, Vermeulen CE, Eggermont AM, et al. Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells. Cell Biochem Biophys 2006; 44: 157-69.
32. van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82: 973-80.
33. Vermorken JB, Guigay J, Mesia R, et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 2011; 104: 1691-6.
34. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-18.
35. Desgrosellier JS, Cheresh DA,. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
36. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610-17.
37. de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80: 161-6.
38. Brunstein F, Hoving S, Seynhaeve AL, et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004; 96: 1603-10.
39. Tjaden UR, de Bruijn EA,. Chromatographic analysis of anticancer drugs. J Chromatogr 1990; 531: 235-94.
40. Goodman SL, Aumailley M, von der Mark H,. Multiple cell surface receptors for the short arms of laminin: alpha 1 beta 1 integrin and RGD-dependent proteins mediate cell attachment only to domains III in murine tumor laminin. J Cell Biol 1991; 113: 931-41.
41. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
42. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
43. Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 320-4.
44. Cheresh DA,. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev 1991; 10: 3-10.
45. Seftor RE, Seftor EA, Gehlsen KR, et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 1557-61.
46. Panetti TS, McKeown-Longo PJ,. The alpha v beta 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 16: 11492-5.
47. Felding-Habermann B, Mueller BM, Romerdahl CA, et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018-22.
48. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-19.
49. Nabors LB, Mikkelsen T, Hegi ME, et al.; for the New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118: 5601-5607.
50. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25: 1651-7.